STADA and SBP Group Formed Biosimilars Partnership
The pharmaceutical firms have established a strategic agreement to develop and market new biosimilar medicines.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you believe corporate partnerships between global pharmaceutical firms improve patient access to affordable medication?
STADA Arzneimittel and SBP Group have entered a strategic partnership to expand the availability of high-value biological medicines. Under the agreement, SBP Group subsidiary CTTQ will handle development and manufacturing while STADA takes the lead on commercialization.
Why it matters
This partnership aims to broaden patient access to advanced biological therapies across multiple international markets. By combining technical manufacturing capabilities with established marketing networks, the firms intend to increase the supply of cost-effective alternatives to existing treatments.
STADA secures exclusive sales and marketing rights across the European Union, Switzerland, the UK, and the Commonwealth of Independent States. The agreement also provides the company with optional exclusive marketing rights for the USA and Gulf Cooperation Council states.
The players
STADA Arzneimittel
This Germany-based pharmaceutical company specializes in generic and specialty medicines.
SBP Group
This is a China-based pharmaceutical organization that operates through various subsidiaries.
CTTQ
This is an innovative pharmaceutical subsidiary of the SBP Group focused on drug development and manufacturing.
The details
CTTQ, the innovative pharmaceutical subsidiary of SBP Group, will manage the full development, manufacturing, and supply chain for the biosimilar candidates. STADA will retain ownership of the marketing authorizations and oversee all distribution activities in the designated regions.
Timeline
September 28, 2026: The partnership was officially announced.
Market Landscape
This deal reflects a broader trend of cross-border alliances where pharmaceutical firms combine regional manufacturing power with established international marketing networks. Such collaborations allow companies to scale production and reach new territories more efficiently than independent expansion.
Patients may eventually see increased availability and competition among biological treatments as these biosimilars reach their markets. While this agreement focuses on corporate logistics, it is designed to facilitate future access to lower-cost pharmaceutical options.
The takeaway
Strategic partnerships between global pharmaceutical firms are becoming essential for managing the high costs and complex regulations associated with biosimilar production. These collaborations ultimately aim to translate technical manufacturing efficiency into improved medicine access for patients worldwide.
Further reading
Explore deeper insights into the sector on our Healthcare page.
Source note: This article includes information reported by Thepharmaletter.
Live Poll
Do you believe corporate partnerships between global pharmaceutical firms improve patient access to affordable medication?
